ExeVir Bio Appoints Michel Kazatchkine and Stef Heylen to the Board of Directors

ExeVir, which is developing nanobody therapies providing broad protection against viral infections, including a lead candidate for coronaviruses, today announced that Michel Kazatchkine and Stef Heylen have been appointed to the Board. Both strengthen ExeVir’s Board by adding pertinent R&D, in depth infectious disease and significant global health experience as ExeVir moves from preclinical to clinical with its lead candidate XVR011.